Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control: Placebo Clear all
Terminated Phase 2 Interventional

The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes

NCT00982293
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resonator device, Resonator device - sham
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT04305587
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-07081532, Placebo, Clopidogrel
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Results available

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

NCT05450198
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
MK-6194, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 21, 2026, 9:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

NCT04056195
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
SKI-O-703, Placebo oral tablet
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort

NCT04955353
View directory record Official record
Conditions
Joint Discomfort
Interventions
AVC-H2, Placebo
Dietary Supplement
Lead sponsor
Avicenna Nutraceutical
Other
Eligibility
40 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 21, 2026, 9:21 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging of Lidoderm for Chronic Back Pain

NCT01515540
View directory record Official record
Conditions
Low Back Pain
Interventions
lidocaine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 4 Interventional Results available

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

NCT00607789
View directory record Official record
Conditions
Binge Eating, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 21, 2026, 9:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective, Multi Centric, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KSM-66 Ashwagandha (Withania Somnifera) in Adults Experiencing High Stress and/or Anxiety

NCT05684991
View directory record Official record
Conditions
Anxiety, Stress
Interventions
KMS-66 Ashwagandha 300mg, placebo capsule
Dietary Supplement
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 1 Interventional

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

NCT02006290
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PF-06412562, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Aventura, Florida • Baco Raton, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 21, 2026, 9:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

NCT04586920
View directory record Official record
Conditions
Healthy
Interventions
LY3509754, Placebo, Itraconazole, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Anaheim, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 21, 2026, 9:21 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 21, 2026, 9:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.

NCT00211770
View directory record Official record
Conditions
Autism
Interventions
Behavioral Assessment
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 4 Interventional Results available

Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes

NCT01576783
View directory record Official record
Conditions
Preterm Birth, Child Development
Interventions
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA), Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
10 Months to 16 Months
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

NCT00839176
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
RX-10100
Drug
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Denver, Colorado • Atlanta, Georgia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
GSK256073, Placebo, Niaspan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

NCT00057213
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Radafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
21
States / cities
Peoria, Arizona • Scottsdale, Arizona • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

NCT02255760
View directory record Official record
Conditions
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Interventions
MEDI3902 - Dose 1, MEDI3902 - Dose 2, MEDI3902 - Dose 3, MEDI3902 - Dose 4, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 21, 2026, 9:21 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917020
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Sep 21, 2026, 9:21 AM EDT